Nature’s Toolbox (NTx) has launched NTx Services, providing high-integrity, complex mRNA production using its innovative NTxscribe® RNA manufacturing system. This service offers rapid turnaround, flexibility, and scalability by utilizing NTx’s continuous flow IVT technology.
NTx Services offers access to the research-grade mRNA manufacturing capabilities of NTxscribe before its commercial launch next year. NTxscribe can produce high-integrity mRNA in just one hour, delivering constructs faster than other service providers. This scalability allows for producing milligram-to-gram quantities of consistently high-integrity mRNA or saRNA.
NTx Services offers competitive pricing compared to traditional batch methods, making it a cost-effective solution. NTxscribe’s continuous flow IVT system streamlines the process and eliminates harmful byproducts, ensuring sustainability. This technology is ideal for research programs focused on RNA-based vaccines or therapies, as it accelerates clinical trials and commercialization.
NTxscribe’s benchtop plug-and-play system features integrated process analytics for real-time monitoring. Its biosynthetic platform provides a scalable manufacturing solution for research and development and commercial levels. The next generation of NTxscribe devices will be available through an early access program this year, with commercial launch anticipated in early 2025. NTx Services empowers researchers and the pharmaceutical industry to advance RNA-based technologies and therapeutic applications by providing faster, more affordable, and scalable mRNA production.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
